Metabolic side effects of antipsychotics and mood stabilizers;Efeitos adversos metabólicos de antipsicóticos e estabilizadores de humor

Revista de Psiquiatria do Rio Grande do Sul

Volumn 28, Issue 2, 2006, Pages 186-196

  Teixeira, Paulo José Ribeiro ^a,b,d   Rocha, Fábio Lopes ^a,c  

^a Instituto de Previdencia Dos Servidores do Estado de Minas Gerais IPSEMG   (Brazil)

^b IPSEMG   (Brazil)

^c UNIVERSITY OF BRASILIA   (Brazil)

^d Rua Fernandes Tourinho   (Brazil)

Author keywords

Antipsychotics; Diabetes mellitus; Dyslipidemia; Metabolic syndrome; Mood stabilizers; Weight gain

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MOLINDONE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENOTHIAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZIPRASIDONE;

ADRENERGIC SYSTEM; BIPOLAR DISORDER; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; MANIA; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33751243943     PISSN: 01018108     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0101-81082006000200011     Document Type: Review

References (61)

1. a ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 4013-47.
2. Keck PE, McElroy SL. Drogas antiepilépticas. In: Schatzberg AF, Nemeroff CB, eds.. Fundamentos de Psicofarmacologia Clínica. Rio de Janeiro: Guanabara Koogan; 2002. p. 178-98.
3. Thonnard-Newmann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry. 1968;124(7):978-82.
4. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol. 1988;8(5):323-30.
5. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61 Suppl 11:37-41.
6. Nasrallah HA, Newcomer JW. Atypical antipsychotic and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24(5 Suppl 1):S7-14.
7. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res. 2003;37(3):193-220.
8. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-72.
9. Wirshing D. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004;65 Suppl 18:13-26.
10. Fontaine KR, Heo M, Harringan EP, Shear CL, Lakshminarayanan M, Casey DE, et al.. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101(3):277-88.
11. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality; results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66(9):1116:21.
12. Flegal, KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight and obesity. JAMA. 2005;293(15):1861-7.
13. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry. 2001;62(6):486-91.
14. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;62 Suppl 23:30-8.
15. Sena EP, Sampaio AS, Quarantini LC, Oliveira IR. Diabetes mellitus e antipsicóticos atípicos. Rev Bras Psiquiatr. 2003;25(4):253-7.
16. Holt RIG, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med. 2004;21(6):515-23.
17. Akhtar S, Kelly C, Gallagher A, Petrie JR. Newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk. Br J Diabetes Vasc Dis. 2004;4(5):303-9.
18. McIntyre RS, Mancini DA, Basile VS, Srinivasan J, Kennedy SH. Antipsychotic-induced weight gain: bipolar disorders and leptin. J Clin Psychopharmacol. 2003;23(4);323-7.
19. Arranz B, Rosel P, Ramírez N, Dueñas R, Fernández P, Sanchez JM, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry. 2004;65(10):1335-42.
20. Isojärvi JI, Rättyä J, Myllylä VV, Knip M, Koivunen R, Pakarinen AJ, et al. Valproate, lamotrigine, and insulinmediated risks in women with epilepsy. Ann Neurol. 1998;43(4):446-51.
21. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al.. Antipsychotic-induced weight gain : a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-96.
22. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a fiveyear naturalistic study. Am J Psychiatry. 2000;157(6):975-81.
23. Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clinical Psychopharmacol. 2002;22(3):244-51.
24. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(10):1837-47.
25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Efectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.
26. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004;65 Suppl18:47-56.
27. th Annual Meeting of the American Psychiatric Association. New York: APA; 2004. Abstract 602.
28. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry. 1988;153:214-7.
29. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Kennedy SH. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord. 2003;5(1):28-35.
30. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci. 1997;24(3):240-4.
31. Lamberti JS, Costea GO, Olson D, Crilly JF, Maharaj K, Tu X, et al. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. J Clin Psychiatry. 2005:66(7):900-6.
32. Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 2002;87(6):2918-23.
33. Newcomer JW, Haupt DW, Melson AK, Schweiger J. Insulin resistance measured with euglycemic clamps during antipsychotic treatment in schizophrenia [abstract]. Biol Psychiatry. 2002;51:25S.
34. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry. 2004;65 Suppl 18:36-46.
35. Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry. 2004;161(2):361-3.
36. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents. Arch Gen Psychiatry. 2005;62(1):19-28.
37. Ardizzone TD, Bradley RJ, Freeman AM 3rd, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine and structural analogs of clozapine. Brain Res. 2001;923(1-2):82-90.
38. Howes OD, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. The effect of clozapine on factors controlling glucose homeostasis. J Clin Psychiatry. 2004;65(10):1352-5.
39. Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotics drugs that inhibit glucose uptake. Pharmacol Biochem Behav. 2003;75(2):255-60.
40. Vestergaard P, Schou M. Does long-term lithium treatment induce Diabetes mellitus? Neuropsychobiology. 1987;17(3):130-2.
41. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol. 2001;11(1):25-32.
42. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol. 2001;16(2):63-73.
43. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus : a pharmacovigilance study. Pharmacotherapy. 2003;23(6):735-44.
44. Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia. 2005;48(2):215-21.
45. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia and hypertension. Arch Gen Psychiatry. 2001;58(12):1172-6.
46. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159(4):561-6.
47. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes mellitus among patients with schizophrenia : population based nested case-control study. BMJ. 2002;325(7358):243.
48. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5):425-33.
49. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical and atypical antipsychotics. Am J Psychiatry. 2003;160(2):290-6.
50. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996;37(1):68-73.
51. Hägg S, Joelsson L, Mjörndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptics. J Clin Psychiatry. 1998;59(6):294-9.
52. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65 Suppl 18:27-35.
53. Sasaki J, Kumagae G, Sata T, Kuramitsu M, Arakawa K. Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines. Atherosclerosis. 1984;51(2-3):163-9.
54. Koro CE, Fedder DO, L'Italien GJ, Weiss, S, Magder LS, Kreyenbuhl J, et al. An assessment of independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59(11):1021-6.
55. Alméras N, Després JP, Villeneuve J, Demers MF, Roy MA, Cadrin C, et al. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry. 2004;65(4):557-64.
56. Heldenberg D, Harel S, Holtzman M, Levtow O, Tamir I. The effect of chronic anticonvulsivant therapy on serum lipids and lipoproteins in epileptic children. Neurology. 1983;33:510-3.
57. Franzoni E, Govoni M, D'Addato S, Gualandi S, Sangiorgi Z, Descovich GC, et al. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs. Epilepsia. 1992;33(5):932-5.
58. Calandre EP, Rodriguez-Lopez C, Blazquez A, Cano D. Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand. 1991;83(4):250-3.
59. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003;28(1):182-92.
60. Casey DE, L'Italien GJ, Cislo P. Incidence of metabolic syndrome in olanzapine and aripiprazole patients. In: 157th Annual Meeting of the American Psychiatric Association. New York: APA; 2004. Abstract 338.
61. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M. Prevalence of metabolic syndrome in hispanic and non-hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry. 2004;6(2):74-7.